The global pediatric cardiac surgery market size was estimated at USD 15.6 billion in 2023 and is projected to grow at a CAGR of 9.8% from 2024 to 2030. The market's growth is primarily driven by the rising incidence of congenital heart defects and heart failure in children. According to the State of Victoria, approximately 1% of newborns are born with a congenital heart defect (CHD), with more than half of these cases requiring treatment due to the severity of the condition. Moreover, as per the Pan American Health Organization study published in March 2023, in the first four weeks of life, an estimated 303,000 newborns die worldwide due to congenital anomalies.
Moreover, increasing enhancements in CPB circuit design, monitoring techniques, perfusion methods, temperature control, and myocardial protection have improved clinical outcomes in pediatric cardiac surgeries. For instance, in April 2024, LivaNova launched the Essenz Perfusion System, a cutting-edge system designed to support open-heart surgery procedures in adult and pediatric patients. It integrates the advanced Essenz Heart-Lung Machine (HLM) with an intuitive Patient Monitor and precise sensing technology. This integration enables data-driven decision-making for safe cardiopulmonary bypass (CBP) management.
Innovations such as specialized pediatric perfusion systems, neonatal CPB oxygenators, low prime volume oxygenators, and integrated arterial filters have improved outcomes and expanded treatment options for complex congenital heart abnormalities in newborns and young children. For instance, in November 2023, Ortho-Clinical Diagnostics announced a 510(k) premarket notification by the FDA for a medical device called “VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrators.” The purpose of these 510(k) submissions is to demonstrate that the VITROS HIV Combo Reagent Pack and Calibrators are substantially equivalent to a predicate device, the VITROS ECi/ECiQ Immunodiagnostic System HIV Combo Assay.
The government is invested in improving pediatric cardiac surgical facilities, further propelling the market growth. For instance, in October 2023, new recommendations were released in the field of congenital heart surgery and were developed under the leadership of the Congenital Heart Surgeons' Society (CHSS). This society is a prestigious organization comprising leading experts in the field. The collaboration involved 15 prominent medical and surgical societies, indicating a comprehensive and multidisciplinary approach to formulating these recommendations.
Increasing investments and funding for producing pediatric perfusion products have also played a crucial role in driving the market growth. Companies are developing cutting-edge procedures and technologies tailored specifically for pediatric CPB, enhancing the quality of care and expanding the range of available treatment options. For instance, in August 2023, Boston Scientific launched the POLAR Cryoablation System, a cutting-edge medical device designed for cardiac surgery, specifically for treating pediatric patients with congenital heart defects. This system utilizes cryoablation technology, which involves freezing tissue to create lesions that can interrupt abnormal electrical pathways in the heart. By receiving FDA approval, Boston Scientific has achieved a significant milestone in advancing pediatric cardiac surgery.
Moreover, there are growing awareness programs for spreading the knowledge and availability of several healthcare facilities for pediatric cardiovascular disorders globally. For instance, the World Congress of Pediatric Cardiology and Cardiac Surgery, a significant international event, was held in August 2023. This event brings together thousands of pediatric cardiologists and pediatric cardiac surgeons from around the world. This congress is considered the most comprehensive, up-to-date, and technologically advanced meeting for pediatric and congenital heart disease. It is a highly anticipated gathering that provides a platform for professionals to engage, share knowledge, discuss advancements, and collaborate on improving care for pediatric patients with heart conditions.
In addition, the recent court ruling in July 2023, allowing the centralization of pediatric heart surgery in the Netherlands, is likely to impact the market significantly. This decision will influence various market aspects, including healthcare infrastructure, patient access to specialized care, competition among healthcare providers, and advancements in pediatric cardiac surgery techniques and technologies.
This product will be delivered within 1-3 business days.
Moreover, increasing enhancements in CPB circuit design, monitoring techniques, perfusion methods, temperature control, and myocardial protection have improved clinical outcomes in pediatric cardiac surgeries. For instance, in April 2024, LivaNova launched the Essenz Perfusion System, a cutting-edge system designed to support open-heart surgery procedures in adult and pediatric patients. It integrates the advanced Essenz Heart-Lung Machine (HLM) with an intuitive Patient Monitor and precise sensing technology. This integration enables data-driven decision-making for safe cardiopulmonary bypass (CBP) management.
Innovations such as specialized pediatric perfusion systems, neonatal CPB oxygenators, low prime volume oxygenators, and integrated arterial filters have improved outcomes and expanded treatment options for complex congenital heart abnormalities in newborns and young children. For instance, in November 2023, Ortho-Clinical Diagnostics announced a 510(k) premarket notification by the FDA for a medical device called “VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrators.” The purpose of these 510(k) submissions is to demonstrate that the VITROS HIV Combo Reagent Pack and Calibrators are substantially equivalent to a predicate device, the VITROS ECi/ECiQ Immunodiagnostic System HIV Combo Assay.
The government is invested in improving pediatric cardiac surgical facilities, further propelling the market growth. For instance, in October 2023, new recommendations were released in the field of congenital heart surgery and were developed under the leadership of the Congenital Heart Surgeons' Society (CHSS). This society is a prestigious organization comprising leading experts in the field. The collaboration involved 15 prominent medical and surgical societies, indicating a comprehensive and multidisciplinary approach to formulating these recommendations.
Increasing investments and funding for producing pediatric perfusion products have also played a crucial role in driving the market growth. Companies are developing cutting-edge procedures and technologies tailored specifically for pediatric CPB, enhancing the quality of care and expanding the range of available treatment options. For instance, in August 2023, Boston Scientific launched the POLAR Cryoablation System, a cutting-edge medical device designed for cardiac surgery, specifically for treating pediatric patients with congenital heart defects. This system utilizes cryoablation technology, which involves freezing tissue to create lesions that can interrupt abnormal electrical pathways in the heart. By receiving FDA approval, Boston Scientific has achieved a significant milestone in advancing pediatric cardiac surgery.
Moreover, there are growing awareness programs for spreading the knowledge and availability of several healthcare facilities for pediatric cardiovascular disorders globally. For instance, the World Congress of Pediatric Cardiology and Cardiac Surgery, a significant international event, was held in August 2023. This event brings together thousands of pediatric cardiologists and pediatric cardiac surgeons from around the world. This congress is considered the most comprehensive, up-to-date, and technologically advanced meeting for pediatric and congenital heart disease. It is a highly anticipated gathering that provides a platform for professionals to engage, share knowledge, discuss advancements, and collaborate on improving care for pediatric patients with heart conditions.
In addition, the recent court ruling in July 2023, allowing the centralization of pediatric heart surgery in the Netherlands, is likely to impact the market significantly. This decision will influence various market aspects, including healthcare infrastructure, patient access to specialized care, competition among healthcare providers, and advancements in pediatric cardiac surgery techniques and technologies.
Global Pediatric Cardiac Surgery Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, the publisher has segmented the global pediatric cardiac surgery market report based on procedure, end-use, and region:- Procedure Outlook (Revenue, USD Million, 2018 - 2030)
- Interventional Procedures
- Peripheral Vascular Procedures
- Heart Rhythm Management Procedures
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Specialty Centers
- Others
- Region Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pediatric Cardiac Surgery Market Variables, Trends & Scope
Chapter 4. Pediatric Cardiac Surgery Market: Procedure Estimates & Trend Analysis
Chapter 5. Pediatric Cardiac Surgery Market: End Use Estimates & Trend Analysis
Chapter 6. Pediatric Cardiac Surgery Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Cedars-Sinai Medical Center
- NYU Langone Hospitals
- Mount Sinai Hospital
- Stanford Health Care-Stanford Hospital
- Heart Center Hirslanden Zurich
- Medical University of Vienna, Department of Cardiology
- University Medical Center Hamburg
- Columbia Asia Hospitals
- Brigham and Women’s Hospital
- Saint Luke’s Mid America Heart Institute
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 15.6 Billion |
| Forecasted Market Value ( USD | $ 29.7 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
